The FTC's long-awaited report published in July was a difficult read for the PBM industry, concluding that the six largest companies in the US market operate a concentrated market structure that ...

Nationally, criticism of PBM practices intensified over the summer with the FTC report. The PCMA pushed back, saying the ...

I say this as a Republican member of Congress who is often critical of the FTC. On this point, however, we are seemingly in lockstep. The FTC’s interim report will help pull back the curtain on ...

Reports of the FTC’s plan come just a couple of days after the regulator published its long-awaited report on the PBM sector, which concluded that their market dominance has “dire consequences ...

The Federal Trade Commission (FTC) on September 27, 2024 unexpectedly withdrew from a recently established Memorandum of Understanding (MOU) with ...

FTC Chairwoman Lina Khan, with her fellow Democratic Commissioners, recently filed a suit against the leading PBMs in an effort to undermine, or even prohibit, their use of rebates to secure ...

Calls for PBM reform focus on transparency and addressing monopolistic practices to improve drug affordability. The FTC's action underscores the need for urgent reforms to address PBMs' anti ...

Current legislation before Congress, including the Modernizing and Ensuring PBM Accountability Act (S.2973) and the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 (S.3430), ...

One exception that enjoys bipartisan support, however, is the effort to rehab the drug supply chain. It’s currently dominated ...

The usual PBM strategy cuts an independent pharmacy's share of the prescription revenue to just 3 cents per pill dispensed, ...